GE Medical completes purchase of Mecon
GE Medical Systems had finalized its acquisition of Mecon, a developer of data mining and Internet-based benchmarking products for the healthcare field. Mecon, of San Ramon, CA, will now operate as a wholly owned subsidiary of GE. As a result of the
GE Medical Systems had finalized its acquisition of Mecon, a developer of data mining and Internet-based benchmarking products for the healthcare field. Mecon, of San Ramon, CA, will now operate as a wholly owned subsidiary of GE. As a result of the merger, Mecon shareholders will receive 0.081 shares of GE stock for each share of Mecon stock held at the close of the merger, plus cash for any fractional shares. David Allinson, Mecons CFO, will assume the role of president and CEO, while Vasu Devan, president and CEO of Mecon since the company was founded, will continue in an advisory capacity.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
